HHS/ASPR Biodefense + Bioterrorism Preparedness News

ASPR

The office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

Biodefense Headlines – 29 September 2024

News Scan September 29, 2024

This edition includes a Marburg virus outbreak in Rwanda, the trajectory of the global H5N1 panzootic, and the public health emergency response to states hit by Hurricane Helene. FEATURED Rwanda Confirms Cases of Marburg Virus Disease, Steps Up Preventive Measures…

ASPR

OraSure Awarded $13.6M From BARDA to Advance COVID-19 Rapid Test

Watch: BARDA Director Talks About Emergency Use Authorization of Third COVID-19 Vaccine

BioFactura Funded $13M Contract Option for Smallpox Biodefense Therapeutic

FDA Authorizes Moderna COVID-19 mRNA Vaccine for Emergency Use

Inflammatix Secures Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test

DRIVE ReDIRECT: Program Seeks to Develop Countermeasures Against Chemical Threats

InBios Awarded $12.7M to Boost Production of Two COVID-19 Diagnostics

BARDA Awards Medical Countermeasures Clinical Studies Network Contracts

FDA Approves First Ebola Therapeutic

MIS-C Detection: BARDA Invests in Rapid Diagnostic for Pediatric Complication of SARS-CoV-2

U.S. Invests in Pandemic Vaccine Manufacturing Capacity with $31M Contract to Cytiva

DoD Expands U.S. Domestic Diagnostics Capacity with $481M Cue Health Deal

BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV

NIH RADx Initiative Advances Six New COVID-19 Testing Technologies

Basilea Awarded Additional Funding from U.S. Medical Countermeasure Program for Ceftobiprole Development

Establishing a Regional Disaster Health Response System in the U.S.

How Are Victims Surviving Novichok Poisoning?

This Atomically Thin Detector Could Become a Biotech Breakthrough

OraSure Gains BARDA Backing for First Rapid COVID-19 Home Testing Kit

JPEO-CBRND, BARDA Partner with SAb Biotherapeutics to Develop COVID-19 Therapeutic

Biodefense Headlines – 29 September 2024